Greenwich LifeSciences, Inc.
$19.25-$0.54 (-2.7%)
Last close · Data as of Nov 20, 2026
- Market cap
- $347.1M
- P/E
- -22.0x
- Revenue
- $0.00
- ROCE
- -631.9%
Price chart
Technical chartScreen technicals →+135.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +18.5%
- 3M
- +25.7%
- 6M
- -29.5%
- 1Y
- +135.9%
- 5Y
- -44.7%
52-week range
Day change -$0.54 (-2.7%) from $20 to $19 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in GLSI, bought on each weekday since 2021.
News & filings
What Greenwich LifeSciences filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 15.8 million US dollars in fiscal 2024.
Strengths (1)
- The company carries almost no debt: debt to equity of 0.00.
- The latest financial year on file is fiscal 2024, which ended more than eighteen months before the latest prices.
- Revenue is too small for margins and growth rates to be read, so those points are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2024
Rule-based from financial data. Not advice.
About the company
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Read moreShow less
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
- Sector
- Healthcare
- Shares outstanding
- 13.2M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $347.1M
- P/E
- -22.0x
- P/B
- 137.0x
- 52-week high
- $33.56
- 52-week low
- $7.85
Profitability
- ROE
- -623.1%
- ROCE
- -631.9%
- ROA
- -385.7%
Growth
- RevenueFY2024, the latest fiscal year in the company's growth history.
- $0.00
- Net profit growth, 1YFY2024, the latest fiscal year in the company's growth history.
- 77.6%
- Free cash flowFY2024, the latest fiscal year in the company's growth history.
- -$7.3M
Solvency
- Current ratio
- 2.62
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- CFO / Net profit
- 0.46
- Cash / Market cap
- 1.2%
Revenue and net profit
Annual revenue, with net profit as the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | $0.00 | -$4.6M |
| FY2022 | $0.00 | -$7.8M |
| FY2023 | $0.00 | -$8.9M |
| FY2024 | $0.00 | -$15.8M |
Cash flows
FY2024: -$7.3M from operations, -$7.3M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | -$4.3M | -$4.3M |
| FY2022 | -$6.2M | -$6.2M |
| FY2023 | -$6.5M | -$6.5M |
| FY2024 | -$7.3M | -$7.3M |
Growth
Latest fiscal year 2024: each figure with its change over the year before.
- Revenue
- $0.00
- EBITDA
- -$16.0M
- Net profit
- -$15.8M
- Cash from operations
- -$7.3M
- Free cash flow
- -$7.3M
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2024 | $0.00 | -$16.0M | -$15.8M | -$7.3M | -623.1% | — | +77.6% |
Monthly returns
Month-by-month returns of GLSI across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2024.
| Line | FY2024 |
|---|---|
| Assets | $4.1M |
| Current assets | $4.1M |
| Non-current assets | $0.00 |
| Liabilities | $1.6M |
| Current liabilities | $1.6M |
| Non-current liabilities | $0.00 |
| Equity | $2.5M |
| Paid-in capital | $68.7M |
| Retained earnings | -$66.2M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; GLSI highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Greenwich LifeSciences, Inc., Atea Pharmaceuticals, Inc., Larimar Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc.GLSIthis company | $347.1M | -22.0x | 137.0x | -623.1% | — |
| Puma Biotechnology, Inc.PBYI | $356.8M | 11.5x | 2.7x | 23.9% | 6.7x |
| REGENXBIO Inc.RGNX | $355.7M | -1.8x | 3.5x | -188.7% | -3.0x |
| Atea Pharmaceuticals, Inc.AVIR | $353.7M | -2.2x | 1.3x | -57.5% | -1.4x |
| Larimar Therapeutics, Inc.LRMR | $341.8M | — | 4.4x | -212.2% | — |
| Enanta Pharmaceuticals, Inc.ENTA | $341.1M | -4.2x | 5.3x | -126.5% | -5.1x |
| Verastem, Inc.VSTM | $339.2M | -1.6x | 5.9x | -366.2% | -1.1x |
| Simulations Plus, Inc.SLP | $336.4M | -5.2x | 2.7x | -51.9% | 20.8x |
| 908 Devices Inc.MASS | $333.5M | 17.1x | 2.3x | 13.6% | -12.6x |
| Peer median | — | -1.8x | 3.1x | -92.0% | -1.4x |
Year-to-date ROI
GLSI since 1 January, against earlier years.
Historical volatility
GLSI's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
| Line | FY2024 |
|---|---|
| RevenueTotal Revenue | $0.00 |
| Operating expensesOperating Expense | $16.0M |
| Research and developmentResearch And Development | $12.9M |
| Selling, general and administrativeSelling General And Administration | $3.1M |
| Total expensesTotal Expenses | $16.0M |
| Operating incomeOperating Income | -$16.0M |
| Interest and other | |
| Pretax incomePretax Income | -$15.8M |
| Tax | |
| Net incomeNet Income | -$15.8M |
| Per share | |
| Supplementary |
| Line | FY2024 |
|---|---|
| AssetsTotal Assets | $4.1M |
| Current assetsCurrent Assets | $4.1M |
| Non-current assetsTotal Non Current Assets | $0.00 |
| LiabilitiesTotal Liabilities Net Minority Interest | $1.6M |
| Current liabilitiesCurrent Liabilities | $1.6M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $0.00 |
| EquityTotal Equity Gross Minority Interest | $2.5M |
| Supplementary |
| Line | FY2024 |
|---|---|
| Operating cash flowOperating Cash Flow | -$7.3M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$7.3M |
| Net income, continuing operationsNet Income From Continuing Operations | -$15.8M |
| Depreciation and amortisationDepreciation And Amortization | $0.00 |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $0.00 |
| Amortization cash flowAmortization Cash Flow | $0.00 |
| Amortization of intangiblesAmortization Of Intangibles | $0.00 |
| Stock-based compensationStock Based Compensation | $7.3M |
| Change in working capitalChange In Working Capital | $1.3M |
| Financing cash flowFinancing Cash Flow | $4.4M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $4.4M |
| Shares issuedIssuance Of Capital Stock | $4.4M |
| Common stock issuedCommon Stock Issuance | $4.4M |
| Net common stock issuedNet Common Stock Issuance | $4.4M |
| Common stock repurchasedCommon Stock Payments | — |
| Share buybacksRepurchase Of Capital Stock | — |
| Stock options exercisedProceeds From Stock Option Exercised | — |
| Other financing chargesNet Other Financing Charges | — |
| Change in cashChanges In Cash | -$2.9M |
| Cash at the start of the yearBeginning Cash Position | $7.0M |
| Cash at the end of the yearEnd Cash Position | $4.1M |
| Free cash flowFree Cash Flow | -$7.3M |
Learn while you research
Academy chapters picked for Greenwich LifeSciences, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read